<table id="t4" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4: Clinically Significant Drug Interactions with ABSTRAL
</caption>
<col align="left" width="20.300%"></col>
<col align="left" width="79.700%"></col>
<tbody>
<tr>
<td align="left" colspan="2" stylecode="Toprule Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Inhibitors of CYP3A4</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The concomitant use of ABSTRAL and CYP3A4 inhibitors can increase the plasma concentration of fentanyl resulting in increased or prolonged opioid effects, particularly when an inhibitor is added after a stable dose of ABSTRAL is achieved <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#s29">5.3</linkhtml>)]</content>.<br/>After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the fentanyl plasma concentration will decrease <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#s88">12.3</linkhtml>)]</content>, resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to fentanyl.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">If concomitant use is necessary, consider dosage reduction of ABSTRAL until stable drug effects are achieved. Monitor patients for respiratory depression and sedation at frequent intervals.<br/>If a CYP3A4 inhibitor is discontinued, consider increasing the ABSTRAL dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir) grapefruit juice.
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">CYP3A4 Inducers</content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The concomitant use of ABSTRAL with CYP3A4 inducers can decrease the plasma concentrations of fentanyl <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#s88">12.3</linkhtml>)]</content>, resulting in decreased efficacy or onset of withdrawal syndrome in patients who have developed physical dependence to fentanyl <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#s32">5.6</linkhtml>)]</content>
<br/>After stopping a CYP3A4 inducer, as the effects of the inducer decline, the fentanyl plasma concentration will increase <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#s88">12.3</linkhtml>)]</content>, which could increase or prolong both the therapeutic effects and adverse reactions, and may cause serious respiratory depression.
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">If concomitant use is necessary, consider increasing the ABSTRAL dosage until stable drug effects are achieved Monitor for signs of opioid withdrawal. If a CYP3A4 inducer is discontinued, consider ABSTRAL dosage reduction and monitor for signs of respiratory depression.
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">rifampin, carbamazepine, phenytoin
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Benzodiazepines and other Central Nervous System (CNS) Depressants</content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death.
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation, <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#s30">5.4</linkhtml>)]</content>.
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Serotonergic Drugs</content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome [<content stylecode="italics">see Warnings and Precautions <linkhtml href="#s38">5.10</linkhtml>].</content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue ABSTRAL if serotonin syndrome is suspected.
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">MAOI interactions with opioids may manifest as serotonin syndrome <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#s38">5.10</linkhtml>)]</content> or opioid toxicity (e.g., respiratory depression, coma) <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#s27">5.1</linkhtml>)].</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The use of ABSTRAL is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">phenelzine, tranylcypromine, linezolid
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">May reduce the analgesic effect of ABSTRAL and/or precipitate withdrawal symptoms.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Avoid concomitant use.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">butorphanol, nalbuphine, pentazocine, buprenorphine
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Toprule Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Muscle Relaxants</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Fentanyl may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of ABSTRAL and/or the muscle relaxant as necessary.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Diuretics</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Monitor patients for signs of diminished diuresis and/or effects on bloodpressure and increase the dosage of the diuretic as needed.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Anticholinergic Drugs</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Monitor patients for signs of urinary retention or reduced gastric motilitywhen ABSTRAL is used concomitantly with anticholinergic drugs.
</td>
</tr>
</tbody>
</table>